NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

PRISM High Risk Smoldering Multiple Myeloma

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma.

The names of the study drugs involved in this study are:

Daratumumab (also called Darzalex Faspro)

Bortezomib (also called Velcade)

Lenalidomide (also called Revlimid)

Dexamethasone

Sponsor:

Omar Nadeem

Collaborator:

Janssen, LP

Information provided by (Responsible Party):